Affinage

IGFBP3

Insulin-like growth factor-binding protein 3 · UniProt P17936

Length
291 aa
Mass
31.7 kDa
Annotated
2026-06-10
100 papers in source corpus 37 papers cited in narrative 37 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

IGFBP3 is a secreted, multifunctional protein that controls insulin-like growth factor (IGF) bioavailability and executes IGF-independent signaling programs governing apoptosis, DNA repair, and tissue homeostasis (PMID:16210470, PMID:28330997). As a carrier, it sequesters extracellular IGF-I and prevents IGF-IR and downstream Akt/MAPK activation; this anti-proliferative effect requires intact IGF binding, as an IGF-binding-deficient mutant fails to block IGF-I signaling, and IGFBP3 levels feed back negatively on TGF-β1- and SND1-driven IGF pathway activation (PMID:16210470, PMID:23831640, PMID:28330997). IGFBP3 carbohydrate occupancy at three N-glycosylation sites (Asn89, Asn109, Asn172) is dispensable for secretion, IGF-I binding, and ALS association (PMID:8817665), and IGF availability is further tuned by proteolysis through ADAM28 and the plasmin system (PMID:30429106, PMID:8817671). Independently of IGF, IGFBP3 is imported to the nucleus by importin-β, where it engages RXRα and stimulates Smad2/3 phosphorylation, and assembles repair complexes with EGFR, DNA-PKcs, NONO and SFPQ that promote non-homologous end-joining — a function that drives resistance to PARP inhibition in prostate cancer (PMID:11376125, PMID:30725116, PMID:38327800). As an apoptosis effector it transduces p53-induced death and drives chondrocyte apoptosis via IGF-independent STAT-1 induction (PMID:12118329, PMID:11886859). Extracellularly, IGFBP3 signals through the death receptor TMEM219 to regulate colonic stem cells and pancreatic beta-cell homeostasis (PMID:26431183, PMID:35115561), inhibits Wnt/GSK-3β/β-catenin signaling in melanoma in a CD44-dependent manner (PMID:27377812), transcriptionally activates the anti-angiogenic factor THBS1 (PMID:32642286), and promotes retinal vascular regrowth and endothelial survival (PMID:17567756, PMID:23868984). Its own expression is induced by hypoxia/HIF-1α via a distal HRE, by p53, insulin, TGF-β/EGFRvIII, and BMP2 pathways, and is restrained by promoter methylation, miR-21, and METTL3-dependent m6A modification (PMID:22415309, PMID:22401581, PMID:25059666, PMID:36657656).

Mechanistic history

Synthesis pass · year-by-year structured walk · 18 steps
  1. 1995 High

    Established the post-translational architecture of IGFBP-3 by mapping which modifications and proteolytic events govern its carrier behavior, clarifying that glycosylation is structurally tolerated rather than functionally required.

    Evidence Site-directed mutagenesis of three N-glycosylation sites with ligand blotting and ALS binding assays; serum proteolysis assays identifying the tPA-plasminogen-plasmin pathway

    PMID:8817665 PMID:8817671

    Open questions at the time
    • Does not address how glycosylation affects nuclear import or non-IGF functions
    • Proteolysis finding rests on a single biochemical assay in review format
  2. 1998 Medium

    Answered how IGFBP3 transcription and mRNA stability are hormonally controlled, linking metabolic signals to IGF-binding capacity.

    Evidence In vitro transcription, gel mobility shift, southwestern blot, and mRNA stability analysis in hepatic nonparenchymal cells

    PMID:9594576

    Open questions at the time
    • Insulin-responsive nuclear factors not molecularly identified
    • Review-format synthesis
  3. 2001 Medium

    Defined a nuclear, IGF-independent mode of action by showing importin-β imports IGFBP-3 to the nucleus where it binds RXRα and engages TGF-β/Smad signaling.

    Evidence Nuclear transport and co-immunoprecipitation studies synthesized in a review

    PMID:11376125

    Open questions at the time
    • Review-format synthesis of primary data
    • Functional consequence of RXRα binding not resolved here
  4. 2002 High

    Connected IGFBP-3 to two distinct apoptotic programs — as the effector of p53-induced apoptosis and as an inducer of IGF-independent STAT-1-mediated death.

    Evidence Inducible p53 cell models with antibody/antisense neutralization; cDNA microarray and IGF-binding-deficient mutant plus antisense STAT-1 knockdown in chondrogenic cells

    PMID:11886859 PMID:12118329

    Open questions at the time
    • Mechanism linking nuclear IGFBP-3 to STAT-1 transcription not defined
    • Cell-type generality of p53 axis untested
  5. 2005 High

    Resolved that IGFBP-3's anti-proliferative effect on IGF signaling is IGF-binding dependent, using a binding-deficient mutant to separate sequestration from receptor-level control.

    Evidence Stable WT vs. GGG (I56G/L80G/L81G) mutant overexpression with IGF-IR/Akt phosphorylation readouts and EGFR inhibitors

    PMID:16210470

    Open questions at the time
    • Does not address IGF-independent functions of the same protein
    • EGF→MAPK suppression mechanism of IGFBP3 not detailed
  6. 2007 High

    Demonstrated IGF-independent tissue protection in vivo by showing IGFBP3 promotes retinal vascular regrowth and endothelial progenitor recruitment.

    Evidence IGFBP3 knockout mice plus exogenous IGFBP3 rescue in an oxygen-induced retinopathy model with vessel and EPC quantification

    PMID:17567756

    Open questions at the time
    • Receptor mediating retinal effect not identified in this study
    • Molecular signaling downstream unresolved
  7. 2009 Medium

    Identified a cancer-cell-targeting metal-binding domain and a neural regulatory role, broadening IGFBP3 functions beyond IGF biology.

    Evidence MBD cross-linking to transferrin receptor, caveolin-1, integrin-β with cytotoxicity and biodistribution assays; transgenic IGFBP3 overexpression with hypocretin/sleep phenotyping

    PMID:19158946 PMID:19342998

    Open questions at the time
    • MBD surface partners not validated as physiological signaling receptors
    • Hypocretin promoter regulation mechanism incomplete
  8. 2012 Medium

    Established hypoxia/HIF-1α and promoter methylation as opposing inducible and silencing controls of IGFBP3 expression in cancer.

    Evidence ChIP, reporter assays and polysome fractionation mapping a -57 kb HRE; bisulfite sequencing and 5-aza demethylation rescue in hepatoblastoma

    PMID:22401581 PMID:22415309

    Open questions at the time
    • Functional output of hypoxia-induced IGFBP3 not assayed in the HRE study
    • Methylation causality in vivo not established
  9. 2013 Medium

    Defined IGFBP3 as a node in negative-feedback and survival circuits across osteosarcoma, retina, and HCC, restraining TGF-β1 and IGF signaling while protecting endothelial cells from apoptosis.

    Evidence Knockdown/overexpression with IGF1R inhibitors (osteosarcoma); IGFBP-3 KO mice with ERG/retinal readouts; receptor siRNA and Co-IP in retinal endothelial cells; SND1 and IGFBP3 knockdown in HCC

    PMID:23291901 PMID:23831640 PMID:23868984 PMID:23878061

    Open questions at the time
    • The retinal IGFBP-3 receptor was not molecularly cloned/identified
    • SND1→IGFBP3 ordering rests on expression analysis without direct binding data
  10. 2015 High

    Identified TMEM219 as a bona fide IGFBP3 death receptor on stem cells and a humanin-importinβ1 axis controlling nuclear entry, defining distinct receptor-dependent and nuclear signaling routes.

    Evidence Organoid assays with recombinant ecto-TMEM219 in diabetic enteropathy models; competitive binding and importin-β1 displacement assays with humanin

    PMID:26216267 PMID:26431183

    Open questions at the time
    • TMEM219 downstream signaling not fully mapped
    • Humanin study confidence Medium and single lab
  11. 2016 Medium

    Extended IGFBP3 signaling to intracellular Wnt suppression and cancer cachexia, showing it can enter cells to activate GSK-3β and that tumor-derived IGFBP3 drives muscle wasting.

    Evidence Recombinant IGFBP-3, Co-IP with GSK-3β, proteasome inhibition and CD44 dependency in melanoma; conditioned medium with knockdown/antibody neutralization in C2C12 cells

    PMID:26975989 PMID:27377812

    Open questions at the time
    • Mechanism of IGFBP3 cell entry via CD44 not biochemically defined
    • Cachexia receptor mediating muscle effect not identified
  12. 2017 Medium

    Clarified transcriptional control of IGFBP3 by nuclear FAK/Runx1 and dissected its dual IGF-dependent/-independent tumor-suppressive activity in lung cancer.

    Evidence FAK-Runx1 Co-IP and reporter assays with nuclear localization models; Igfbp3-null x Kras mice and WT vs. binding-deficient mutant overexpression in NSCLC

    PMID:28330997 PMID:28807942

    Open questions at the time
    • IGF-independent component of the lung effect not mechanistically pinpointed
    • FAK/Runx1 epigenetic partners only partially defined
  13. 2018 Medium

    Established proteolytic and SUMOylation-based control points: ADAM28 degrades IGFBP-3 to release IGF-I, and SUMO2/3 directs IGFBP-3-dependent nuclear translocation of IGF-1R under stress.

    Evidence ADAM28 knockdown/knockout with degradation and xenotransplantation assays; SUMOylation assays and nuclear fractionation in corneal epithelial cells

    PMID:30078228 PMID:30429106

    Open questions at the time
    • SUMO sites on IGFBP-3/IGF-1R not mapped
    • Physiological scope of nuclear IGF-1R unclear
  14. 2019 High

    Defined the DNA-repair complex and a hyperglycemia-driven cardiac apoptosis circuit, showing IGFBP-3 promotes NHEJ via NONO/SFPQ/EGFR/DNA-PKcs and mediates HIF1α/ROS-dependent IGF sequestration in cardiomyocytes.

    Evidence LC-MS/MS interactome, reciprocal Co-IP, PLA, cell-free binding and end-joining assays with PARP/EGFR/DNA-PKcs inhibitors; Co-IP, siRNA/antibody rescue and diabetic rat echocardiography

    PMID:30659610 PMID:30725116

    Open questions at the time
    • How nuclear IGFBP-3 nucleates the repair complex structurally is unknown
    • Cardiac axis is Medium-confidence single lab
  15. 2020 Medium

    Mapped additional inducers (BMP2/ALK3/ID1) and effectors (THBS1, MMP2, hepatic lipid droplets), positioning IGFBP3 in angiogenesis, stromal migration, and steatosis.

    Evidence Inducible IGFBP3 with THBS1 siRNA and angiogenesis assays distinguishing intracellular vs. extracellular promoter activation; sequential BMP2/ALK3/ID1/IGFBP3 knockdowns; HSC-selective NRP-1 KO with recombinant IGFBP3 hepatocyte treatment

    PMID:32087348 PMID:32642286 PMID:32975335

    Open questions at the time
    • Intracellular signaling activating THBS1 transcription not defined
    • Receptor mediating hepatocyte lipid response unidentified
  16. 2022 High

    Confirmed TMEM219 as a beta-cell death receptor for IGFBP3 and uncovered roles in mitochondrial homeostasis and aging-related smooth muscle pathology.

    Evidence TMEM219 KO mice plus pharmacological IGFBP3/TMEM219 blockade with patient validation; gain/loss-of-function with Seahorse flux and sBNIP3L/NIX assays in corneal cells; IGFBP3 knockdown in aged CCSMCs

    PMID:34918377 PMID:35115561 PMID:35154570

    Open questions at the time
    • TMEM219 intracellular signaling cascade incompletely defined
    • Mitochondrial and CCSMC mechanisms are Medium/Low confidence single lab
  17. 2023 Medium

    Identified m6A/METTL3 post-transcriptional control and a c-Jun-driven TGF-β/EGFRvIII positive feedback loop driving IGFBP3 in fibrosis and glioblastoma.

    Evidence MeRIP-seq with METTL3/IGFBP3 knockdown in cardiac fibrosis models; ChIP for c-Jun binding to the IGFBP3 promoter with Smad/ERK pathway dissection

    PMID:36657656 PMID:37192967

    Open questions at the time
    • m6A reader mediating IGFBP3 stabilization not identified
    • Feedback loop receptor/ligand stoichiometry unresolved
  18. 2024 Medium

    Demonstrated that IGFBP3-driven EGFR/DNA-PKcs DNA repair confers PARP inhibitor resistance, giving therapeutic relevance to its nuclear repair function.

    Evidence Olaparib-resistant prostate cancer cells with IGFBP3 siRNA, gefitinib phenocopy, γH2AX and viability assays

    PMID:38327800

    Open questions at the time
    • Direct molecular link between IGFBP3 and EGFR activation not biochemically resolved
    • In vivo resistance reversal not shown

Open questions

Synthesis pass · forward-looking unresolved questions
  • The molecular identity and signaling logic of the non-TMEM219 'IGFBP-3 receptor' (e.g., the retinal endothelial receptor) and the structural basis by which nuclear IGFBP-3 nucleates transcription and DNA-repair complexes remain unresolved.
  • Retinal IGFBP-3 receptor not molecularly cloned
  • No structure of nuclear IGFBP-3 in complex with RXRα or NONO/SFPQ
  • Mechanism of cell entry for intracellular functions undefined

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0098772 molecular function regulator activity 4 GO:0140313 molecular sequestering activity 4 GO:0060089 molecular transducer activity 3 GO:0048018 receptor ligand activity 2
Localization
GO:0005576 extracellular region 4 GO:0005634 nucleus 4 GO:0005829 cytosol 1
Pathway
R-HSA-162582 Signal Transduction 4 R-HSA-1643685 Disease 4 R-HSA-5357801 Programmed Cell Death 4 R-HSA-73894 DNA Repair 2
Partners
EGFRGSK3BIGF1IGF1RNONORXRASFPQTMEM219
Complex memberships
IGF-1/IGFBP3/ALS ternary complexNuclear IGFBP3-NONO-SFPQ-EGFR-DNA-PKcs DNA-repair complex

Evidence

Reading pass · 37 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2015 IGFBP3 binds its receptor TMEM219 on colonic stem cells (CoSCs) in an IGF-I-independent manner, leading to disruption of CoSC function and prevention of organoid growth in vitro; restoration of normal IGFBP3/IGF-I levels rescued CoSC homeostasis. In vitro organoid growth assay, recombinant ecto-TMEM219 protein treatment, preclinical diabetic enteropathy model, proteomic profiling of patient serum Cell stem cell High 26431183
2022 IGFBP3 signals through the death receptor TMEM219 on pancreatic beta cells, causing beta cell loss and dysfunction; genetic ablation of TMEM219 or pharmacological blockade of IGFBP3/TMEM219 preserved beta cell mass and prevented/delayed diabetes onset in preclinical models. TMEM219 knockout mice, in vitro beta cell treatment, in vivo IGFBP3/TMEM219 inhibition, patient cohort validation Nature communications High 35115561
2002 IGFBP3 (using an IGF-binding-deficient mutant) upregulates STAT-1 mRNA and protein expression, induces STAT-1 phosphorylation and nuclear localization, and this IGF-independent STAT-1 induction mediates IGFBP3-induced apoptosis in chondrogenic cells; antisense STAT-1 oligonucleotides abolished IGFBP3-induced apoptosis. cDNA microarray, Northern blot, transfection with IGFBP3 mutant unable to bind IGFs, antisense oligonucleotide knockdown, immunolocalization The Journal of biological chemistry High 11886859
2002 IGFBP-3 mediates p53-induced apoptosis during serum starvation; inhibition of IGFBP-3 with antibody or antisense oligomers reduced apoptosis to levels comparable to p53 degradation, and IGF-I co-treatment blocked IGFBP-3-dependent apoptosis. Doxycycline-inducible p53 model (p53-negative PC-3 cells), stable E6-transfected H460 cells to degrade p53, anti-IGFBP-3 antibody neutralization, IGFBP-3 antisense oligomers International journal of oncology High 12118329
2019 IGFBP-3 forms nuclear complexes with NONO and SFPQ (DNA/RNA-binding proteins) in a PARP-dependent and EGFR/DNA-PKcs-dependent manner in triple-negative breast cancer cells, promoting DNA double-strand break repair by non-homologous end-joining; PARP inhibitors and LINP1 siRNA blocked these interactions. LC-MS/MS interactome analysis, co-immunoprecipitation, proximity ligation assay, cell-free biochemical binding assay, DNA end-joining in vitro assay, γH2AX foci measurement, EGFR/DNA-PKcs inhibitors, PARP inhibitors, siRNA Cellular and molecular life sciences : CMLS High 30725116
2012 Hypoxia induces IGFBP3 mRNA transcription in esophageal squamous cancer cells via HIF-1α binding to a novel hypoxia-responsive element (HRE) at -57 kb upstream of the transcription start site; IGFBP3 mRNA is enriched in polysomes enabling continued cap-dependent translation under hypoxia, despite global protein synthesis suppression. RNA interference (HIF-1α/HIF-2α siRNA), chromatin immunoprecipitation (ChIP), transfection/luciferase assays, metabolic labeling, 7-methyl GTP-cap binding assay, mTOR inhibitors, bicistronic RNA reporter, polysome fractionation FASEB journal High 22415309
2005 EGF suppresses IGFBP-3 mRNA and protein expression through MAPK activation in an EGFR-tyrosine kinase-dependent manner; secreted IGFBP-3 neutralizes IGFs and prevents IGF-I receptor activation; wild-type but not IGF-binding-deficient (I56G/L80G/L81G) IGFBP-3 prevents IGF-I from activating IGF-IR and Akt, demonstrating that IGFBP-3's anti-proliferative effect on IGF signaling is IGF-binding dependent. Stable overexpression of wild-type vs. GGG mutant IGFBP-3, EGFR inhibitors, Western blot for IGF-IR and Akt phosphorylation, cell proliferation assays American journal of physiology. Gastrointestinal and liver physiology High 16210470
2013 TGF-β1 induces IGFBP-3 expression in osteosarcoma cells, and IGFBP-3 in turn attenuates TGF-β1 activation of ERK1/2 and Akt, inhibits TGF-β1-induced cell cycle progression and proliferation; blocking IGF1R signaling abolishes IGFBP-3's effect, and blocking IGFBP-3 induction enhances nuclear Smad2 phosphorylation — establishing a negative-feedback loop. IGFBP-3 knockdown/overexpression, IGF1R inhibition, Western blot for ERK1/2, Akt, pSmad2, cell cycle and proliferation assays Molecular and cellular endocrinology Medium 23831640
2016 IGFBP-3 inhibits Wnt signaling in metastatic melanoma cells by entering the cell, binding the Wnt signalosome component GSK-3β, dissociating the β-catenin destruction complex from the LRP6 receptor, activating GSK-3β through dephosphorylation, and targeting cytoplasmic β-catenin for proteasomal degradation; this effect depends on CD44. Recombinant IGFBP-3 treatment of cultured melanoma cells, co-immunoprecipitation with GSK-3β, β-catenin immunofluorescence/Western blot, proteasome inhibition, CD44 dependency assay, mouse xenograft Molecular carcinogenesis Medium 27377812
2017 Nuclear FAK cooperates with Runx1 to regulate IGFBP3 transcription in squamous cell carcinoma; FAK forms a molecular complex with Runx1 and interacts with Sin3a and other epigenetic modifiers that alter Runx1 transcriptional function, thereby controlling IGFBP3-dependent cell-cycle progression and tumor growth. Co-immunoprecipitation (FAK-Runx1 nuclear complex), genetic FAK nuclear localization models, luciferase reporter, in vivo tumor growth assays Cancer research Medium 28807942
2015 Humanin binds directly to IGFBP3 (Kd ~5.05 µM) and both humanin and its analogue HN 3-19 interfere with the binding of importin-β1 to IGFBP3 in vitro (IC50 ~18.1 µM and ~10.3 µM respectively), thereby blocking IGFBP3 nuclear translocation and reducing apoptosis in lung adenocarcinoma cells. Competitive ligand dot blotting, co-immunoprecipitation, ELISA-based binding assay, apoptosis assay in lung adenocarcinoma cells Protein and peptide letters Medium 26216267
2001 IGFBP-3 can be transported to the nucleus by an importin-β-mediated mechanism where it interacts with retinoid X receptor alpha (RXRα); IGFBP-3 antiproliferative signaling requires an active TGF-β signaling pathway and stimulates phosphorylation of TGF-β signaling intermediates Smad2 and Smad3. Transfection, nuclear transport assays, co-immunoprecipitation/interaction studies (review citing primary experimental data) Molecular pathology : MP Medium 11376125
2007 In oxygen-induced retinopathy, IGFBP3 acts independently of IGF-1 to prevent vessel loss and promote vascular regrowth; IGFBP3-deficient mice showed dose-dependent increase in retinal vessel loss and 31% decrease in vessel regrowth, while exogenous IGFBP3 increased vessel regrowth correlating with a 30% increase in endothelial progenitor cells in the retina. IGFBP3 knockout mice, exogenous IGFBP3 administration, oxygen-induced retinopathy model, retinal vessel quantification, endothelial progenitor cell quantification Proceedings of the National Academy of Sciences of the United States of America High 17567756
2013 IGFBP-3 and TNF-α work antagonistically in retinal endothelial cells: IGFBP-3 inhibits apoptosis while TNF-α promotes it; loss of IGFBP-3 signaling (IGFBP-3 KO mice) results in increased retinal apoptosis, decreased B-wave and oscillatory potential amplitudes, reduced retinal thickness, and elevated TNF-α levels. IGFBP-3 knockout mice, electroretinogram, retinal cell counting, treatment of retinal endothelial cells with IGFBP-3 and TNF-α Investigative ophthalmology & visual science Medium 23868984
2013 IGFBP-3 inhibits retinal endothelial cell (REC) death through activation of a specific IGFBP-3 receptor; siRNA knockdown of the IGFBP-3 receptor increased cell death, and IGFBP-3 overexpression upregulated IGFBP-3 receptor protein levels; co-immunoprecipitation confirmed IGFBP-3 and receptor binding; IGFBP-3 modulated Bcl-xL, Bax, cytochrome C and Akt in a receptor-dependent manner. IGFBP-3 receptor siRNA knockdown, IGFBP-3 plasmid overexpression (non-IGF-binding mutant), co-immunoprecipitation, cell death ELISA, caspase-3 ELISA, Western blot Apoptosis Medium 23291901
2009 IGFBP3 co-localizes with and regulates hypocretin (orexin) in hypothalamic neurons; transgenic mice overexpressing human IGFBP3 show decreased hypocretin mRNA, peptide content, and increased sleep, possibly mediated through decreased hypocretin promoter activity in the presence of excess IGFBP3. Gene expression profiling (microarray), in vivo transgenic overexpression, hypocretin mRNA and peptide quantification, sleep phenotyping, promoter activity assay PloS one Medium 19158946
2020 IGFBP3 mediates lipid droplet formation and triglyceride accumulation in hepatocytes; recombinant IGFBP3 (secreted by activated hepatic stellate cells) induced lipid droplets and lipogenic genes in hepatocytes in vitro; NRP-1 deletion from HSCs reduced IGFBP3 secretion and protected hepatocytes from ethanol-induced steatosis. HSC-selective NRP-1 knockout (ColCre/Nrp1loxP mice), adipokine/inflammatory protein array, recombinant Igfbp3 treatment of hepatocytes, in vitro lipid droplet/triglyceride measurement, alcohol feeding model Journal of hepatology Medium 32087348
2014 miR-21 directly targets IGFBP3 mRNA and downregulates IGFBP3 expression in glioblastoma; IGFBP3 overexpression inhibited tumor cell proliferation in vitro and xenograft growth in vivo; IGFBP3 knockdown in miR-21-knockdown cells restored tumorigenesis, placing IGFBP3 as a downstream effector of miR-21. Microarray, 3'-UTR luciferase reporter (miR-21 target validation), overexpression and knockdown of IGFBP3, rescue/epistasis experiment, xenograft mouse model The Journal of biological chemistry Medium 25059666
2017 IGFBP3 modulates lung tumor progression through IGF1 signaling; Igfbp3-null mice combined with Kras showed >2-fold increased lung tumor burden; overexpression of IGFBP3 in NSCLC cells induced apoptosis (10-fold increase in cleaved caspase-3) and inactivated IGF1 and MAPK signaling; IGF-binding-deficient IGFBP3 mutant partially retained activity, indicating both IGF-dependent and -independent mechanisms. Igfbp3-null mouse model crossed with Kras, overexpression of WT vs. IGF-binding-deficient mutant IGFBP3 in NSCLC cells, cleaved caspase-3 measurement, IGF1/MAPK signaling Western blot, cisplatin response assay Molecular cancer research : MCR High 28330997
2016 Pancreatic cancer cell-derived IGFBP-3 causes muscle wasting via IGF signaling inhibition; IGFBP-3 treatment of C2C12 muscle cells impaired myogenesis and enhanced muscle protein degradation; IGFBP3 knockdown in pancreatic cancer cells or antibody neutralization of IGFBP-3 in conditioned medium alleviated wasting. Conditioned medium from Capan-1 pancreatic cancer cells, IGFBP3 knockdown (siRNA), anti-IGFBP-3 antibody neutralization, myogenesis and protein degradation assays in C2C12 cells Journal of experimental & clinical cancer research : CR Medium 26975989
1995 IGFBP-3 has three N-glycosylation sites (Asn89, Asn109, Asn172); site mutagenesis shows ~4, 5, and 6 kDa of carbohydrate at sites 1, 2, and 3 respectively; glycosylation is not required for secretion or IGF-I binding; the two native IGFBP-3 forms represent protein glycosylated at all three sites vs. only at Asn89/Asn109; glycosylation does not significantly affect acid-labile subunit (ALS) binding. Site-directed mutagenesis of N-glycosylation sites, ligand blotting with [125I]IGF-I, radioimmunoassay, ALS binding assay, expression in CHO cells Progress in growth factor research High 8817665
1995 IGFBP-3 in serum undergoes proteolytic degradation by the tissue plasminogen activator (tPA)-plasminogen-plasmin system, providing an additional mechanism for regulation of IGF bioavailability. Serum proteolysis assays with tPA-plasminogen-plasmin pathway identification Progress in growth factor research Low 8817671
2018 IGFBP-3 mediates nuclear translocation of IGF-1R in corneal epithelial cells in response to growth factor withdrawal via SUMOylation by SUMO 2/3; IGF-1R and IGFBP-3 undergo reciprocal regulation independent of PI3K/Akt signaling; under growth conditions IGFBP-3 arrests the cell cycle in G0/G1, while under stress it maintains nuclear IGF-1R levels. Growth factor withdrawal model, SUMOylation assays (SUMO 2/3), nuclear fractionation, cell cycle analysis, PI3K/Akt inhibition Journal of cellular physiology Medium 30078228
2022 IGFBP-3 regulates mitochondrial homeostasis in corneal epithelial cells through control of the sBNIP3L/NIX mitophagy receptor; both loss and gain of IGFBP-3 function increase mitochondrial respiration; nuclear accumulation of IGFBP-3 is associated with increased respiration; IGFBP-3 also regulates lamellar cristae morphology and mitochondrial dynamics. Loss-of-function (siRNA/KD) and gain-of-function (overexpression) of IGFBP-3, Seahorse metabolic flux analysis, mitochondrial morphology imaging, sBNIP3L/NIX assays, nuclear fractionation FASEB journal Medium 34918377
2021 IGFBP-3 mediates metabolic homeostasis in corneal epithelial cells under hyperosmolar stress; hyperosmolarity decreases IGFBP-3 expression; supplementation with recombinant IGFBP-3 abrogates metabolic and mitochondrial changes (altered calcium, depolarization, decreased ATP and mtDNA) induced by hyperosmolar stress. hTCEpi cell hyperosmolar stress model, Seahorse metabolic flux analysis, mitochondrial calcium/polarization/mtDNA assays, ELISA for IGFBP-3 and cytokines, recombinant IGFBP-3 supplementation, LDH cytotoxicity assay Investigative ophthalmology & visual science Medium 34100890
2019 ROS- and HIF1α-dependent IGFBP3 upregulation under hyperglycemia leads to IGFBP3 secretion, sequestration of extracellular IGF1, blockade of IGF1 pro-survival signaling, and cardiomyocyte apoptosis; siRNA against IGFBP3 or anti-IGFBP3 antibody rescued cardiac apoptosis; HIF1α inhibition downregulated IGFBP3; PHD regulates HIF1α stability upstream of IGFBP3. Co-IP (IGF1-IGFBP3 extracellular association), Western blot, siRNA (IGFBP3, HIF1α), anti-IGFBP3 antibody, ROS scavenger, diabetic rat model, echocardiography Journal of cellular physiology Medium 30659610
2023 METTL3 promotes IGFBP3 expression via N6-methyladenosine (m6A) mRNA modification in cardiac fibroblasts; METTL3 silencing downregulates IGFBP3 and inhibits cardiac fibroblast activation; IGFBP3 knockdown inhibits migration and proliferation of cardiac fibroblasts. MeRIP-seq (m6A sequencing), METTL3 silencing, IGFBP3 knockdown, transverse aortic constriction and isoproterenol cardiac fibrosis models, migration/proliferation assays European journal of pharmacology Medium 36657656
2012 IGFBP3 promoter methylation epigenetically silences IGFBP3 expression in hepatoblastoma (HB) cell lines; treatment with 5-aza-2'-deoxycytidine restored IGFBP3 expression; restoring IGFBP3 in HB cells reduced colony formation, migration, and invasion; IGFBP3 promoter methylation predominantly occurred in metastatic HB with vascular invasion. Bisulfite sequencing of IGFBP3 promoter CpGs, 5-aza-2'-deoxycytidine demethylation, IGFBP3 re-expression in cell lines, colony formation, migration and invasion assays Molecular cancer Medium 22401581
2009 IGFBP-3 contains a 22-amino acid metal-binding domain (MBD) that selectively targets cancer cells via cell surface cross-linking to transferrin receptor, caveolin 1, and integrin-β; MBD uptake rate correlates with gene expression of stress-response pathways (NF-κB, Hsp-70B); MBD-tagged cytotoxic peptides show selective cytotoxicity to cancer vs. normal cells and reduce tumor burden in mouse models. MBD cross-linking to cell surface receptors, correlation with NCI-60 gene array data, cytotoxicity assays, in vivo biodistribution, mouse leukemia/melanoma dissemination models Anti-cancer drugs Medium 19342998
2020 IGFBP3 inhibits angiogenesis by activating THBS1 (thrombospondin-1) transcription through intracellular signaling; IGFBP3 induction increased THBS1 in epithelial ovarian cancer cells; THBS1 silencing reversed IGFBP3-induced inhibition of capillary tube formation (HUVEC assay) and chick CAM vessel development; luciferase assay showed intracellular IGFBP3 more potently activated THBS1 promoter than extracellular IGFBP3. Inducible IGFBP3 expression system, THBS1 siRNA, HUVEC tube formation assay, chick CAM assay, xenograft, luciferase promoter assay American journal of cancer research Medium 32642286
2020 BMP2 upregulates IGFBP3 expression in human endometrial stromal cells via ALK3 receptor and the transcription factor ID1; IGFBP3 in turn promotes MMP2 expression and cell migration; knockdown of IGFBP3 or ID1 suppressed BMP2-induced MMP2 upregulation and cell migration. Immortalized and primary human endometrial stromal cells, BMP2 dose-response, ALK3 knockdown, ID1 knockdown, IGFBP3 knockdown, MMP2 measurement, migration assays FASEB journal Medium 32975335
1998 Insulin increases IGFBP-3 gene transcription in hepatic nonparenchymal cells via an insulin-responsive element that recruits insulin-responsive nuclear factors (demonstrated by gel mobility shift assay and southwestern blot); IGF-I increases IGFBP-3 mRNA stability (post-transcriptional regulation). In vitro transcription assays, gel mobility shift assay, southwestern blot, mRNA stability analysis Progress in nucleic acid research and molecular biology Medium 9594576
2018 ADAM28 promotes IGF-I-induced leukemia cell proliferation by degrading IGFBP-3, thereby increasing free IGF-I availability; ADAM28 knockout reduced leukemic cell growth and dissemination in a xenotransplantation model. ADAM28 knockdown/knockout in leukemic cells, IGFBP-3 degradation assay, IGF-I proliferation assay, xenotransplantation mouse model Cancer letters Medium 30429106
2023 TGF-β and EGFRvIII transactivation in glioblastoma cells activates c-Jun transcription factor via Smad2/3 and ERK1/2 pathways, which binds the IGFBP3 promoter to promote IGFBP3 production and secretion; IGFBP3 knockdown inhibited TGF-β/EGFRvIII signaling and malignant behaviors, revealing a positive feedback loop. TGF-β treatment of GBM cells, co-immunoprecipitation (Smad2/3, ERK1/2), ChIP (c-Jun binding to IGFBP3 promoter), IGFBP3 knockdown, in vitro/in vivo tumor assays iScience Medium 37192967
2024 IGFBP3 promotes resistance to the PARP inhibitor olaparib in prostate cancer by enhancing DNA repair capacity through activation of EGFR and DNA-PKcs; IGFBP3 depletion reduces EGFR/DNA-PKcs activity, increases DNA damage accumulation, and re-sensitizes resistant cells to olaparib; gefitinib (EGFR inhibitor) phenocopies IGFBP3 inhibition. Olaparib-resistant cell line development, IGFBP3 siRNA knockdown, EGFR inhibition (gefitinib), DNA-PKcs assay, γH2AX foci, cell viability assays iScience Medium 38327800
2013 SND1 knockdown in hepatocellular carcinoma cells increases IGFBP3 expression; increased IGFBP3 negatively regulates IGF pathway activation by restricting IGF-receptor interactions; conversely, IGFBP3 knockdown promotes cell proliferation, placing IGFBP3 downstream of SND1 as a negative regulator of IGF signaling in HCC. Stable SND1 shRNA knockdown, IGFBP3 stable knockdown, real-time PCR screening of IGF pathway genes, proliferation and tumor formation assays Anatomical record Low 23878061
2022 IGFBP3 knockdown in aged corpus cavernosum smooth muscle cells (CCSMCs) increased cell viability and proliferation while decreasing apoptosis, oxidative stress, and fibrosis, identifying IGFBP3 upregulation with aging as a driver of these pathological processes in erectile dysfunction. siRNA knockdown of IGFBP3 in primary aged CCSMCs, flow cytometry (apoptosis), EdU/CCK-8 (proliferation), ROS assay, Western blot, immunofluorescence Oxidative medicine and cellular longevity Low 35154570

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2010 Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. The Lancet. Oncology 520 20472501
2007 IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth. Proceedings of the National Academy of Sciences of the United States of America 143 17567756
2009 Perspectives in mammalian IGFBP-3 biology: local vs. systemic action. American journal of physiology. Cell physiology 140 19279229
2001 Signalling pathways involved in antiproliferative effects of IGFBP-3: a review. Molecular pathology : MP 139 11376125
2005 IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer. Human molecular genetics 137 16306136
2014 MicroRNA-21 promotes glioblastoma tumorigenesis by down-regulating insulin-like growth factor-binding protein-3 (IGFBP3). The Journal of biological chemistry 136 25059666
2015 Insulin-like growth factor binding-protein-3 (IGFBP-3). Best practice & research. Clinical endocrinology & metabolism 130 26522455
2005 Essential roles of IGFBP-3 and IGFBP-rP1 in breast cancer. European journal of cancer (Oxford, England : 1990) 120 15979304
2004 Associations among IRS1, IRS2, IGF1, and IGFBP3 genetic polymorphisms and colorectal cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 94 15247132
2020 Insulin Growth Factor Binding Protein 7 (IGFBP7)-Related Cancer and IGFBP3 and IGFBP7 Crosstalk. Frontiers in oncology 85 32500027
2000 P53 and IGFBP-3: apoptosis and cancer protection. Molecular genetics and metabolism 85 10873390
1998 Molecular regulation of insulin-like growth factor-I and its principal binding protein, IGFBP-3. Progress in nucleic acid research and molecular biology 82 9594576
2006 Characterization of the expression of the hypoxia-induced genes neuritin, TXNIP and IGFBP3 in cancer. FEBS letters 80 16723126
2008 Progesterone regulates FGF10, MET, IGFBP1, and IGFBP3 in the endometrium of the ovine uterus. Biology of reproduction 79 18753603
2020 Salvianolic acid B improves myocardial function in diabetic cardiomyopathy by suppressing IGFBP3. Journal of molecular and cellular cardiology 77 31982427
2019 IGFBP-3 interacts with NONO and SFPQ in PARP-dependent DNA damage repair in triple-negative breast cancer. Cellular and molecular life sciences : CMLS 71 30725116
2016 Genomewide meta-analysis identifies loci associated with IGF-I and IGFBP-3 levels with impact on age-related traits. Aging cell 70 27329260
2015 Circulating IGF-I and IGFBP3 Levels Control Human Colonic Stem Cell Function and Are Disrupted in Diabetic Enteropathy. Cell stem cell 69 26431183
2016 IGFBP3 and MAPK/ERK signaling mediates melatonin-induced antitumor activity in prostate cancer. Journal of pineal research 63 27736013
2009 IGFBP3 colocalizes with and regulates hypocretin (orexin). PloS one 61 19158946
2014 IGFBP-3: a cell fate pivot in cancer and disease. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society 59 24953254
2021 IGF-1 and IGFBP-3 in Inflammatory Cachexia. International journal of molecular sciences 58 34502376
2020 Hepatic stellate cell activation promotes alcohol-induced steatohepatitis through Igfbp3 and SerpinA12. Journal of hepatology 58 32087348
2007 IGF-1 and IGFBP-3 gene variants influence on serum levels and prostate cancer risk in African-Americans. Carcinogenesis 53 17724372
2022 The IGFBP3/TMEM219 pathway regulates beta cell homeostasis. Nature communications 49 35115561
2017 Nuclear FAK and Runx1 Cooperate to Regulate IGFBP3, Cell-Cycle Progression, and Tumor Growth. Cancer research 49 28807942
2011 Serum IGF1, IGF2 and IGFBP3 and risk of advanced colorectal adenoma. International journal of cancer 48 21932422
2017 IGFBP3 Modulates Lung Tumorigenesis and Cell Growth through IGF1 Signaling. Molecular cancer research : MCR 47 28330997
2012 Hypoxia induces IGFBP3 in esophageal squamous cancer cells through HIF-1α-mediated mRNA transcription and continuous protein synthesis. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 46 22415309
2009 Association of IGF1 and IGFBP3 polymorphisms with colorectal polyps and colorectal cancer risk. Cancer causes & control : CCC 46 19784788
2016 Pancreatic cancer cell-derived IGFBP-3 contributes to muscle wasting. Journal of experimental & clinical cancer research : CR 45 26975989
2002 Identification of STAT-1 as a molecular target of IGFBP-3 in the process of chondrogenesis. The Journal of biological chemistry 45 11886859
2020 Hsa_circ_0046263 functions as a ceRNA to promote nasopharyngeal carcinoma progression by upregulating IGFBP3. Cell death & disease 44 32703944
2019 Suppression of tumor growth via IGFBP3 depletion as a potential treatment in glioma. Journal of neurosurgery 43 30641835
2013 IGFBP-3 and TNF-α regulate retinal endothelial cell apoptosis. Investigative ophthalmology & visual science 40 23868984
2009 Common genetic variation in IGF1, IGFBP1 and IGFBP3 and ovarian cancer risk. Carcinogenesis 40 19858071
2014 Aflatoxin exposure is inversely associated with IGF1 and IGFBP3 levels in vitro and in Kenyan schoolchildren. Molecular nutrition & food research 39 24668606
2012 IGFBP3 impedes aggressive growth of pediatric liver cancer and is epigenetically silenced in vascular invasive and metastatic tumors. Molecular cancer 39 22401581
2023 IGFBP3 epigenetic promotion induced by METTL3 boosts cardiac fibroblast activation and fibrosis. European journal of pharmacology 38 36657656
2002 IGFBP-3 mediates p53-induced apoptosis during serum starvation. International journal of oncology 38 12118329
2011 IGF1 and IGFBP3 in acute respiratory distress syndrome. European journal of endocrinology 37 22004906
2014 Insulin-like growth factor pathway genetic polymorphisms, circulating IGF1 and IGFBP3, and prostate cancer survival. Journal of the National Cancer Institute 36 24824313
2013 TGF-β-induced expression of IGFBP-3 regulates IGF1R signaling in human osteosarcoma cells. Molecular and cellular endocrinology 35 23831640
2002 The effects of tonsillectomy and adenoidectomy on serum IGF-I and IGFBP3 levels in children. The Laryngoscope 35 12150629
1995 The role of glycosylation in the action of IGFBP-3. Progress in growth factor research 34 8817665
2018 B-Myb Mediates Proliferation and Migration of Non-Small-Cell Lung Cancer via Suppressing IGFBP3. International journal of molecular sciences 33 29772705
2021 TRAIP modulates the IGFBP3/AKT pathway to enhance the invasion and proliferation of osteosarcoma by promoting KANK1 degradation. Cell death & disease 32 34349117
2020 Graphene Oxide Nanoparticles Induce Apoptosis in wild-type and CRISPR/Cas9-IGF/IGFBP3 knocked-out Osteosarcoma Cells. Journal of Cancer 32 32742448
2020 Circ_0000285 regulates proliferation, migration, invasion and apoptosis of osteosarcoma by miR-409-3p/IGFBP3 axis. Cancer cell international 32 33041662
2019 ROS- and HIF1α-dependent IGFBP3 upregulation blocks IGF1 survival signaling and thereby mediates high-glucose-induced cardiomyocyte apoptosis. Journal of cellular physiology 32 30659610
2009 Promoter methylation of IGFBP-3 and p53 expression in ovarian endometrioid carcinoma. Molecular cancer 31 20003326
2005 EGF-mediated regulation of IGFBP-3 determines esophageal epithelial cellular response to IGF-I. American journal of physiology. Gastrointestinal and liver physiology 31 16210470
2020 The regulation of IGFBP3 by BMP2 has a role in human endometrial remodeling. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 30 32975335
2010 IGFBP3 and BAG1 enhance radiation-induced apoptosis in squamous esophageal cancer cells. Biochemical and biophysical research communications 30 21195059
2021 IGF-I/IGFBP3/ALS Deficiency in Sarcopenia: Low GHBP Suggests GH Resistance in a Subgroup of Geriatric Patients. The Journal of clinical endocrinology and metabolism 28 33378445
2015 Humanin Peptide Binds to Insulin-Like Growth Factor-Binding Protein 3 (IGFBP3) and Regulates Its Interaction with Importin-β. Protein and peptide letters 28 26216267
2021 XBP1- IGFBP3 Signaling Pathway Promotes NSCLC Invasion and Metastasis. Frontiers in oncology 25 34094948
2014 Targeted mass spectrometry analysis of the proteins IGF1, IGF2, IBP2, IBP3 and A2GL by blood protein precipitation. Journal of proteomics 25 25277046
2018 IGFBP-3 plays an important role in senescence as an aging marker. Environmental toxicology and pharmacology 24 29579543
1995 Serum proteolysis of IGFBP-3. Progress in growth factor research 24 8817671
2022 Upregulated IGFBP3 with Aging Is Involved in Modulating Apoptosis, Oxidative Stress, and Fibrosis: A Target of Age-Related Erectile Dysfunction. Oxidative medicine and cellular longevity 22 35154570
2022 BMI and Contraceptives Affect New Age-, Sex-, and Puberty-adjusted IGF-I and IGFBP-3 Reference Ranges Across Life Span. The Journal of clinical endocrinology and metabolism 22 35294528
2021 IGFBP-3 Mediates Metabolic Homeostasis During Hyperosmolar Stress in the Corneal Epithelium. Investigative ophthalmology & visual science 22 34100890
2018 RSRC1 mutation affects intellect and behaviour through aberrant splicing and transcription, downregulating IGFBP3. Brain : a journal of neurology 22 29522154
2018 Mutual regulation between IGF-1R and IGFBP-3 in human corneal epithelial cells. Journal of cellular physiology 22 30078228
2013 SND1 affects proliferation of hepatocellular carcinoma cell line SMMC-7721 by regulating IGFBP3 expression. Anatomical record (Hoboken, N.J. : 2007) 22 23878061
2019 Testis-specific protein, Y-linked 1 activates PI3K/AKT and RAS signaling pathways through suppressing IGFBP3 expression during tumor progression. Cancer science 21 30815935
2007 IGFBP3 mRNA expression in benign and malignant breast tumors. Breast cancer research : BCR 21 17210081
2024 METTL3 inhibitor suppresses the progression of prostate cancer via IGFBP3/AKT pathway and synergizes with PARP inhibitor. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20 39232384
2020 IGFBP3 inhibits angiogenesis through intracellular regulation of THBS1 expression. American journal of cancer research 20 32642286
2015 The association between circulating IGF1, IGFBP3, and calcium: results from NHANES III. Endocrine connections 20 26304028
2024 Elevated expression of WSB2 degrades p53 and activates the IGFBP3-AKT-mTOR-dependent pathway to drive hepatocellular carcinoma. Experimental & molecular medicine 19 38177295
2016 IGFBP-3 inhibits Wnt signaling in metastatic melanoma cells. Molecular carcinogenesis 19 27377812
2010 Influence of IGFBP3 gene polymorphisms on IGFBP3 serum levels and the risk of prostate cancer in low-risk Korean men. Urology 19 20350746
2009 IGFBP3 polymorphisms and risk of cancer: a meta-analysis. Molecular biology reports 19 19449212
2022 IGFBP-3 functions as a molecular switch that mediates mitochondrial and metabolic homeostasis. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 18 34918377
2020 IGFBP-3 stimulates human osteosarcoma cell migration by upregulating VCAM-1 expression. Life sciences 18 33188835
2019 Predictive and targeting value of IGFBP-3 in therapeutically resistant prostate cancer. American journal of clinical and experimental urology 17 31317059
2018 Investigation of IGF1, IGF2BP2, and IGFBP3 variants with lymph node status and esophagogastric junction adenocarcinoma risk. Journal of cellular biochemistry 17 30335898
2018 ADAM28 promotes tumor growth and dissemination of acute myeloid leukemia through IGFBP-3 degradation and IGF-I-induced cell proliferation. Cancer letters 17 30429106
2023 Doxorubicin induced ROS-dependent HIF1α activation mediates blockage of IGF1R survival signaling by IGFBP3 promotes cardiac apoptosis. Aging 16 36602546
2013 Regulation of retinal endothelial cell apoptosis through activation of the IGFBP-3 receptor. Apoptosis : an international journal on programmed cell death 16 23291901
2024 CDK12 regulates angiogenesis of advanced prostate cancer by IGFBP3. International journal of oncology 15 38186306
2022 Roles of IGFBP-3 in cell migration and growth in an endophytic tongue squamous cell carcinoma cell line. Scientific reports 15 35798794
2020 MiR-384 Inhibits Malignant Biological Behavior Such as Proliferation and Invasion of Osteosarcoma by Regulating IGFBP3. Technology in cancer research & treatment 15 32129151
2019 Regulation of IGF-I by IGFBP3 and IGFBP5 during odontoblast differentiation in mice. Journal of oral biosciences 15 31400542
2024 IGFBP3 promotes resistance to Olaparib via modulating EGFR signaling in advanced prostate cancer. iScience 14 38327800
2009 The metal-binding domain of IGFBP-3 selectively delivers therapeutic molecules into cancer cells. Anti-cancer drugs 14 19342998
2009 The expression and function of IGFBP-3 in normal and malignant breast tissue. Anticancer research 14 19846909
2020 Associations of plasma IGF1, IGFBP3 and estradiol with leucocyte telomere length, a marker of biological age, in men. European journal of endocrinology 13 31658437
2015 Circulating IGF1 and IGFBP3 in relation to the development of β-cell autoimmunity in young children. European journal of endocrinology 13 25947142
2014 Induction of apoptosis by IGFBP3 overexpression in hepatocellular carcinoma cells. Asian Pacific journal of cancer prevention : APJCP 13 25556430
2010 IGF1, IGFBP1, and IGFBP3 genes and mammographic density: the Multiethnic Cohort. International journal of cancer 13 20039319
2007 Epigenetic and functional analysis of IGFBP3 and IGFBPrP1 in cellular immortalization. Biochemical and biophysical research communications 13 17451653
2023 IGFBP3 induced by the TGF-β/EGFRvIII transactivation contributes to the malignant phenotype of glioblastoma. iScience 12 37192967
2019 Igfbp3 in grass carp (Ctenopharyngodon idellus): Molecular identification and mRNA expression under glucose, insulin and glucagon. Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology 12 31866567
2018 Effects of IGFBP3 gene silencing mediated inhibition of ERK/MAPK signaling pathway on proliferation, apoptosis, autophagy, and cell senescence in rats nucleus pulposus cells. Journal of cellular physiology 12 30370550
2010 IGFBP3 A-202C polymorphism and breast cancer susceptibility: a meta-analysis involving 33,557 cases and 45,254 controls. Breast cancer research and treatment 12 20084546
2022 SALIS transcriptionally represses IGFBP3/Caspase-7-mediated apoptosis by associating with STAT5A to promote hepatocellular carcinoma. Cell death & disease 11 35871161
2020 IGFBP3 gene promoter methylation analysis and its association with clinicopathological characteristics of colorectal carcinoma. Molecular biology reports 11 32929656

Missed literature

Know a paper Affinage missed for IGFBP3? Flag it for the maintainers and the community.

No submissions yet.